
    
      This is an open-label, single center, non-randomized, phase I trial to evaluate the safety
      and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the
      recurrent or metastatic nasopharyngeal carcinoma.

      Safety evaluations (both clinical and laboratory) are performed at baseline, before each
      study treatment, and throughout the study.Tumor response will be assessed by radiographic
      examination in screening visit and every 2 cycles after first dose.
    
  